

PRODUCT Update

NEWLY AVAILABLE HPV ASSAY

BD Onclarity™ HPV Assay detects all 14 of the high-risk HPV genotypes, including types 16 and 18, which contribute to 70% of cervical cancers. As more women



are vaccinated against HPV, the prevalence of types 16 and 18 have declined. HPV 31 has a higher risk for pre-cervical cancer than HPV 18, however, and can go undetected. Unlike other cervical cancer assays, **BD Onclarity™ HPV Assay** does not pool HPV 31 with other types of HPV, allowing clinicians to individually detect high-risk HPV-31. The **BD Onclarity™ HPV Assay** gives clinicians the ability to identify a woman's risk more precisely for developing cervical pre-cancer and cancer, and therefore, manage better outcomes for patients, says the manufacturer.

FOR MORE INFORMATION, VISIT:

<https://womens-health-solutions.bd.com/>